Skip Navigation

Advertise|Press|Contact|FAQ|About Us

Bookmark/Print/Share

Home » Clinical Trials » Location » Oregon » Portland

Clinical Trial Details

Overview

Research Study Summary

Patients are needed to participate in a clinical research study of UshStat to evaluate Usher Syndrome or Retinitis Pigmentosa

Research Study Title

A Phase I/IIa Dose Escalation Safety Study of Subretinally Injected UshStat, Administered to Patients With Retinitis Pigmentosa Associated With Usher Syndrome Type 1B

Purpose

The purpose of this first in man study is to examine the safety of an experimental gene transfer agent, UshStat designed to treat retinitis pigmentosa associated with Usher Syndrome Type 1B.

To Learn more
Phase

1/2

Gender

Both Male and Female

Age

18 and up

Overall Status

Recruiting

Lead Sponsor

Sanofi

Duration

60 Months

Facility Type

N/A

Eligibility

Both Male and Female ages 18 Years and up

Inclusion Criteria:

  • Clinical and molecular diagnosis of Retinitis Pigmentosa associated with Usher Syndrome type 1B. With at least one pathogenic mutation in the MYO7A gene on each chromosome.

  • Suitable verbal, auditory,written and/or tactile sign language communication as to allow informed consent to be obtained.

  • Women of childbearing potential must agree to use two forms of contraception.

  • Males must agree to use two forms of contraception if their study partner is of child-bearing potential for three months after treatment.

  • Affiliated with the French social security healthcare system (french patients only)

Exclusion Criteria:

  • Presence of significant ocular abnormalities that would preclude surgery, effective study follow up or interfere with study endpoints.

  • Concomitant systemic diseases that can alter visual function.

  • Contraindication to pupil dilation, anesthesia or eye surgery.

  • Periocular steroids in the last four months prior to screen.

  • Known allergies to the components of the delivery vehicle or diagnostic agents such as dilation drops.

  • Life-threatening illness or a history of malignancy within 5 years

  • Laboratory test abnormalities that would make the patient unsuitable for participation in the study

  • Intercurrent illnesses or infections 28 days prior to treatment

  • Concurrent anti-retroviral or immunosuppressant therapy

  • Men or women who do not agree to use contraception as specified in the inclusion criteria.

  • Pregnant or breastfeeding women

  • Enrollment in any other clinical study during the 48 week study period

  • Treatment with anticoagulants

  • Past history of HIV or hepatitis A, B or C

  • Inability to comply with the demands of the study

  • Any ocular surgery in the study eye within 6 months

Site Locations (2)

Country State City Zip Facility and Contact
United States Oregon Portland 97239-4197 Oregon Health & Science University

Richard Weleber, MD
Principal Investigator
France Paris 75571 Central Hospitalier Nationale d'Opthalmolgie des Quinze-Vingts

Jose Sahel, MD
Principal Investigator

Contact

Richard Weleber, MD
503-494-7887

NCT ID: NCT01505062

Date Last Changed: June 24, 2014

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials. Some study summaries have been edited for clarity purposes to make them easier to understand. View more study details here.